Joseph A. Gogos, M.D., Ph.D.
Dr. Gogos is an assistant professor at Columbia University Center for Neurobiology and Behavior. He received an M.D. from the National University of Greece and a Ph.D. from Harvard University. Dr. Gogos is a leading authority on the genetic and biological basis of schizophrenia. His research is aimed at identifying genes that influence the processing of sensory information by the mammalian brain and the decoding of this information into specific behaviors. His work also focuses on understanding how sensory processing and integration is affected in psychiatric disease states and elucidating the genetic basis of these deficits. A major goal of his research is to gain understanding of the biological function of schizophrenia susceptibility elements through analysis at the cellular, physiological and behavioral levels. Dr. Gogos provides unique insight on the mechanistic basis of schizophrenia and related psychiatric disorders.

Tetsuro Kikuchi, D.V.M., Ph.D.
Dr. Kikuchi is a Director of Quests Research Institute of Otsuka Pharmaceutical Co. Ltd. in Tokushima, Japan. Dr. Kikuchi has a degree in veterinary medicine and received a Ph.D. in veterinary pharmacology from Gifu University. Dr. Kikuchi is an authority on behavioral pharmacology and antipsychotic drug development and played a leading role in the discovery of aripiprazole, a new and highly successful atypical antipsychotic drug. His current research is focused on further development of novel antipsychotic compounds. Dr. Kikuchi provides expertise in all phases of psychiatric disease drug discovery.

Robert D. McQuade, Ph.D.
Dr. McQuade is a Senior Vice President of Global Medical Affairs of Otsuka Pharmaceutical Development & Commercialization, Inc. in Princeton, New Jersey. He received his B.S. degree from Davidson College (Davidson NC) and his Ph.D. from the University of North Carolina. Dr. McQuade began his career at Schering-Plough Pharmaceuticals, where his research focused on the discovery of new drugs for the treatment of schizophrenia and Alzheimer’s disease. Subsequently, he moved to Bristol-Myers Squibb Co. in the department of Global Medical Affairs, where he was responsible for the global medical affairs of the antidepressant, nefazodone (Serzone), the anxiolytic, buspirone (Buspar) and more recently the antipsychotic, aripiprazole (Abilify). Dr. McQuade relocated to Otsuka in 2004, where he is responsible for global medical affairs for aripiprazole, as well as for compounds in late-stage development for the treatment of congestive heart failure and ulcerative colitis, and early-stage approaches to the treatment of schizophrenia and depression. Dr. McQuade brings over 20 years of pharmaceutical experience in the discovery, development and marketing of drugs for the treatment of mental illness.

Susumu Tonegawa, Ph.D.
Dr. Tonegawa, 1987 Nobel Prize winner in Medicine, is a professor at the Massachusetts Institute of Technology (MIT), director of the RIKEN-Picower-MIT Center for Neural Circuit Genetics, and a Howard Hughes Medical Institute Investigator. His expertise spans the fields of immunology and neuroscience. In the area of neuroscience, he has pioneered the use of genetically modified mice to understand the molecular basis of learning and memory. Recent advances in his laboratory include the development of a variety of animal models to study cognitive and psychiatric diseases. Dr. Tonegawa is a scientific founder of Galenea and provides specific expertise in molecular and behavioral neuroscience and mouse molecular genetic technology.